Nationwide multicenter survey on the pathophysiology of hospital-acquired pneumonia and the use of first-line antibiotics in Japan: Evaluation of clinical position of meropenem in the initial therapy of hospital-acquired pneumonia

DOI IR HANDLE 7 Citations 24 References
  • Kohno Shigeru
    Department of Molecular Microbiology and Immunology, Division of Molecular and Clinical Microbiology, Nagasaki University Graduate School of Medical Sciences
  • Watanabe Akira
    Department of Respiratory Medicine, Institute of Development, Aging and Cancer, Tohoku University
  • Matsushima Toshiharu
    川崎医科大学呼吸器内科
  • HAP Study Group

Bibliographic Information

Other Title
  • 全国多施設での院内肺炎の実態と初期治療におけるｍｅｒｏｐｅｎｅｍの位置づけ
  • Evaluation of clinical position of meropenem in the initial therapy of hospital-acquired pneumonia

Search this article

Abstract

Through a nationwide, collaborative, multicenter survey to investigate the pathophysiological profile of hospital-acquired pneumonia (HAP) and the use of first-line antibiotics, we evaluated the clinical position of meropenem (MEPM) in the initial therapy of HAP. A prospective survey was conducted of consecutivelyenrolled patients with HAP in the period from June 2002 to May 2004. Data were collected for a total of 1, 460 patients from 254 institutions across Japan.Among the cases analyzed for patient profiles (1356 patients), 661 cases were treated with MEPM among the first-line antibiotic. Of the MEPM-treated cases, monotherapy accounted for 76.6%. Among cases treated with MEPM combination therapy, clindamycin was used in 24.5%, followed in descending order by tetracyclines and aminoglycosides. MEPM was preferably used for serious cases or cases having many risk factors defined in the Japanese Respiratory Society Guidelines for Management of HAP in Adults. As for the distribution of the disease type, moderate pneumonia with a risk factor or severe pneumonia [Group III: type C] and pneumonia with specific conditions [Group IV: type D-H] accounted for 91.7% of all cases. The response rate was 54.4% when MEPM was used as a first-line medication, and 47.2% when carbapenems were not used. Most of the MEPM-treated patients were the dosage which is normal in Japan (0.25-0.5g×2/day). As the main causative organisms of HAP were antibioticresistant bacteria such as Pseudomonas aeruginosa, future revisions of the HAP guideline should incorporate consideration of antibiotics dosage based on the PK/PD theory. As for safety, main adverse drug reactions in MEPM-treated patients were hepatic function disorder. Unlabelled serious adverse drug reactions were not reported. In conclusion, the results from this study suggest that MEPM plays an important role in the initial therapy of HAP.

Journal

Citations (7)*help

See more

References(24)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top